PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs...
PhaseRx reported revenue of $0 for fiscal year 2016, down 100.0% from fiscal year 2015, and net income of -$20.14 million.
Figures from company filings; latest fiscal year ended December 31, 2016.
From state WARN notices, SEC filings and news reports. Reported: news reports only. Confirmed: an official filing exists.
PhaseRx had 0 layoffs in the last 12 months, and 1 in all (the earliest dated October 13, 2017).
Layoffs, 12 months
0
Workers not stated
Layoffs in all
1
Earliest dated Oct 13, 2017
Workers in all
10
Where the sources state it
Newest layoff
Oct 13, 2017
Announced date
| Date | Place | Workers | Status | Sources |
|---|---|---|---|---|
| Oct 13, 2017 | United States | 10 | Confirmed | SEC 8-K |
No profile data available.